Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition.

ABSTRACT:

Background

Although many efforts have been devoted to identify biomarkers to predict the responsiveness of immune checkpoint inhibitors, including expression of programmed death-ligand 1 (PD-L1) and major histocompatibility complex (MHC) I, microsatellite instability (MSI), mismatch repair (MMR) defect, tumor mutation burden (TMB), tertiary lymphoid structures (TLSs), and several transcriptional signatures, the sensitivity of these indicators remains to be further improved.

Materials and methods

Here, we integrated T-cell spatial distribution and intratumor transcriptional signals in predicting the response to immune checkpoint therapy in MMR-deficient tumors including tumors of Lynch syndrome (LS).

Results

In both cohorts, MMR-deficient tumors displayed personalized

SUBMITTER: Zheng G 

PROVIDER: S-EPMC10175608 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature